Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company develops targeted therapies for liver and viral diseases, with a primary focus on chronic hepatitis B virus (CHB) infection, a large unmet medical need affecting hundreds of millions of people worldwide.
Its lead program is pevifoscorvir sodium, a small-molecule capsid assembly modulator (CAM-E) being evaluated as a potential best- or first-in-class treatment for CHB. The candidate has received FDA Fast Track Designation and is advancing through the Phase 2 B-SUPREME study. Aligos is also developing an antisense oligonucleotide candidate, ALG-170675, which has entered Phase 1 studies in China through its partnership with Amoytop. Because the company has no commercialized products, investors follow the stock for clinical data readouts, regulatory milestones, and the strength of its balance sheet rather than near-term revenue. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, ALGS shares have fallen approximately 60%, declining from around $5.23 in mid-October to about $2.10 in mid-November 2026. The move was not gradual: the stock traded in a relatively narrow range through most of October before a sharp sell-off in the first half of November, when the stock lost more than half of its value in a matter of days.
The last quarter tells a similar, if steeper, story. Roughly three months ago, shares were changing hands near $6.77, meaning the stock has declined close to 69% over that span. This quarterly decline extends a longer downtrend: ALGS traded well above $13 earlier in the year and has since moved toward the lower end of its 52-week range, reflecting sustained pressure on both the business and investor sentiment. From what I see, the pattern aligns with broader biotech volatility.
The most significant catalyst behind the recent decline was the company's third-quarter report, released in early November 2026. On the surface, the results contained positive elements: GAAP net loss narrowed to $21.9 million from $31.5 million a year earlier, revenue rose to roughly $2.8 million from $741,000, and the per-share loss of $(2.09) exceeded consensus expectations.
However, the accompanying disclosures dominated the market's reaction. In its quarterly filing, Aligos reported $31.1 million in cash, cash equivalents, and investments, down sharply from $77.8 million at the end of 2025, and stated that these resources are expected to fund operations only into the first quarter of 2027. Management also disclosed substantial doubt about its ability to continue as a going concern and indicated plans to raise additional capital. Because the pivotal B-SUPREME topline data is not expected until late in the third quarter of 2027, the financing gap is well ahead of the next major clinical catalyst, intensifying investor concerns about near-term dilution.
Over the last quarter, the broader narrative has been defined by the tension between clinical progress and a deteriorating balance sheet. Earlier in 2026, the stock had benefited from a series of positive developments, including the Amoytop licensing agreement with up to $420 million in potential milestone payments, FDA Fast Track Designation for pevifoscorvir sodium, and encouraging interim data from the Phase 2 B-SUPREME study.
Those catalysts were progressively outweighed by a steady decline in cash reserves and a data timeline that stretches further out than the company's available runway. Active financing instruments, including an at-the-market program and a shelf registration, added a persistent dilution overhang. As the cash position narrowed quarter over quarter, sentiment shifted from pipeline optimism toward financing risk, and the share price steadily gave back its earlier gains before the sharp November sell-off. I’m watching this closely as the dilution risk remains front and center.
The most important near-term factor for ALGS is financing. Any announcement regarding a new capital raise, the use of its at-the-market facility, or restructuring of its cash runway will likely shape the stock's direction and determine the extent of shareholder dilution.
Beyond financing, investors should monitor the Phase 2 B-SUPREME study of pevifoscorvir sodium, with topline data anticipated in late third-quarter 2027, as well as progress of the ALG-170675 antisense oligonucleotide program in China. Additional milestone payments from the Amoytop partnership could also provide non-dilutive capital. Finally, broader conditions in the biotech financing market and sentiment toward clinical-stage small-cap companies will influence the company's ability to bridge its funding gap. These are informational factors to monitor, not a basis for investment decisions.
In my own research, I often turn to Tickeron’s AI Trading Bots to simulate different strategies on volatile names like this. The platform offers a range of options that can help gauge potential market reactions across hundreds of bots. It provides a practical way to explore automated approaches without replacing core fundamental analysis.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
ALGS saw its Momentum Indicator move below the 0 level on November 05, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned negative. In 82 of the 89 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for ALGS turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 44 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALGS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ALGS entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALGS advanced for three days, in 186 of 237 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
ALGS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Seasonality Score of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.797) is normal, around the industry mean (3.586). P/E Ratio (-0.528) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.680) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. ALGS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALGS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology